Search reports, ask a question, or jump to a page.
The problem
Intervention: Development of a pediatric fixed-dose combination tablet containing dolutegravir, emtricitabine, and tenofovir alafenamide for children weighing 3-20 kg
Who it was tested with: Children aged 0-14 years weighing 3-20 kg living with HIV.
Experience from people who deliver programmes: stories, case studies and lessons learned. Valuable for understanding how and why, and for spotting what to test next, but not a measure of effect.
"Population pharmacokinetic models were used for exposure simulation of DTG, TAF, and its metabolite tenofovir. The adequacy of the proposed FDC was based on whether the simulated drug exposures met predefined efficacy and safety targets." This describes a modeling simulation approach to predict whether a proposed drug combination would achieve adequate therapeutic levels while maintaining safety.
This is a simulation-based study without clinical trial data, so predictions of exposure adequacy and safety have not been verified in actual children. A subset of children under 3 months had simulated emtricitabine doses exceeding approved maximums, indicating potential limitations for very young infants.
Across countries and designs
1 study · 0 countries
